Earnings calls

Mankind Pharma concall ledger

Every earnings call for MANKIND — management tone, guidance, KPIs and promise tracking, quarter by quarter.

MANKIND · 4 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 03 Feb 2026Call held 03 Feb 2026

MANKIND Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹3,567 cr+12% YoYAdjusted EBITDA Margin25.9%PAT₹414 cr+10% YoYGross Margin72.6%

Revenue ₹3,567 cr (+12% YoY); Adjusted EBITDA Margin 25.9%; PAT ₹414 cr (+10% YoY). Q3 revenue grew 11.5% YoY to INR3,567 crores, with 9M revenue up 18.7% YoY to INR10,835 crores.

Read full transcript & analysis

Q2 FY26Published 06 Nov 2025Call held 06 Nov 2025

MANKIND Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹3,697 cr+21% YoYEBITDA₹924 cr+9% YoYEBITDA Margin25%−3% YoYPAT₹520 cr−21% YoYEPS₹12.4

Revenue ₹3,697 cr (+21% YoY); EBITDA ₹924 cr (+9% YoY); EBITDA Margin 25.0% (−3% YoY). Overall revenue increased 21% YoY to INR 3,697 crores in Q2 FY26.

Read full transcript & analysis

Q1 FY26Published 01 Aug 2025Call held 01 Aug 2025

MANKIND Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹3,570 cr+25% YoYEBITDA₹850 cr+26% YoYEBITDA Margin23.8%−1% YoYPAT₹445 cr−17% YoYGross Margin70.5%−1% YoY

Revenue ₹3,570 cr (+24% YoY); EBITDA ₹850 cr (+26% YoY); EBITDA Margin (Adjusted) 23.8% (−1% YoY). Overall revenues increased to ₹3,570 crores, up 24.5% YoY.

Read full transcript & analysis

Q4 FY25Published 27 May 2025Call held 27 May 2025

MANKIND Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹3,079 cr+27% YoYAdjusted EBITDA Margin23.1%PAT₹429 cr−10% YoY

Revenue ₹3,079 cr (+27% YoY); Adjusted EBITDA Margin 23.1%; PAT ₹429 cr (−10% YoY). Q4 FY25 Revenue grew 27% YoY to INR3,079 crores.

Read full transcript & analysis